Drilldown: Medicines

Other values:

Search

None (83) · Coumadin (discontinued in US but name in common use), Jantoven (1) · Delysid (historical, Sandoz, withdrawn 1965) (1) · Eliquis (1) · Xarelto (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

5-HT2A agonist (26) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · Monoamine releasing agent (3) · Serotonin releasing agent; 5-HT2A agonist (3) · Serotonin/norepinephrine/dopamine releasing agent (3) · Contains LSA (2) · Contains mescaline (2) · Serotonin releasing agent (2)

Other values:

Search

None (84) · '"`UNIQ--vote-000001F8-QINU`"', '"`UNIQ--vote-000001F9-QINU`"', '"`UNIQ--vote-000001FA-QINU`"' (1) · '"`UNIQ--vote-0000050F-QINU`"', '"`UNIQ--vote-00000510-QINU`"', '"`UNIQ--vote-00000511-QINU`"', '"`UNIQ--vote-00000512-QINU`"' (1) · '"`UNIQ--vote-00000700-QINU`"', '"`UNIQ--vote-00000701-QINU`"', '"`UNIQ--vote-00000702-QINU`"', '"`UNIQ--vote-00000703-QINU`"', '"`UNIQ--vote-00000704-QINU`"' (1)

None (84) · NVAF: 20 mg PO once daily with the evening meal (15 mg if CrCl 15-50); acute VTE: 15 mg BID for 21 days, then 20 mg daily; CAD/PAD: 2.5 mg BID with aspirin (1) · NVAF: 5 mg PO BID (2.5 mg BID if 2 of 3: age ≥80, weight ≤60 kg, serum creatinine ≥1.5 mg/dL); acute VTE: 10 mg BID for 7 days, then 5 mg BID (1) · Typical 5 mg PO daily; 2.5 mg in elderly, low body weight, malnutrition, hepatic dysfunction. Genotype-guided initial dosing per CPIC/IWPC algorithms (CYP2C9, VKORC1, CYP4F2) is one of the most-established PGx applications in current practice (1)

None (84) · 1, 2, 2.5, 3, 4, 5, 6, 7.5, 10 mg tablets (color-coded by strength) (1) · 2.5 mg, 5 mg tablets (1) · 2.5, 10, 15, 20 mg tablets (1)

None (84) · 10 mg BID for the first 7 days of acute VTE; otherwise 5 mg BID (1) · 30 mg/d (acute VTE first 21 days as 15 mg BID); otherwise 20 mg/d (1) · No fixed maximum; titrated to INR target (1)

None (83) · IV (rarely used; same dose) (1) · Oral (4)

None (83) · 30–60 minutes (1) · Anticoagulant effect at 24-72 hours; full INR effect 5-7 days (1) · Peak anticoagulant effect 2-4 hours (1) · Peak anticoagulant effect 3-4 hours (1)

None (83) · 12 hours (1) · 2-5 days after stopping (factor II resynthesis-limited) (1) · 24 hours (1) · 8–12 hours (1)

None (83) · 36-42 hours (R/S enantiomers differ; S-warfarin is 2-5× more potent and cleared by CYP2C9)'"`UNIQ--ref-00000705-QINU`"' (1) · 3–5 hours (1) · 5-9 hours (elderly: 11-13 hours)'"`UNIQ--ref-00000513-QINU`"' (1) · ~12 hours'"`UNIQ--ref-000001FB-QINU`"' (1)

None (83) · 70–90% (oral) (1) · ~100% (oral)'"`UNIQ--ref-00000706-QINU`"' (1) · ~50% (oral; not significantly affected by food)'"`UNIQ--ref-000001FC-QINU`"' (1) · ~80-100% with food at 15-20 mg doses (10 mg dose: ~80% without food); '''must be taken with food''' at therapeutic doses'"`UNIQ--ref-00000514-QINU`"' (1)

None (85) · Avoid in pregnancy; switch to LMWH. Crosses placenta; warfarin-class concerns about fetal hemorrhage and teratogenicity make heparins the preferred class.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Not established (1)

None (83) · Schedule I (United States) (1) · [[USLegal:Prescription only|Rx-only]] in US (3)